title: Revealing targeted therapeutic opportunities in triple-negative breast cancers: a new strategy.
authors: Department of Clinical Cancer Prevention; The University of Texas MD Anderson Cancer Center; Houston, TX USA.
authors: Graham M
authors: GM
authors: Poage
authors: Zachary C
authors: ZC
authors: Hartman
authors: Powel H
authors: PH
authors: Brown
mesh_terms: D000818:Animals; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000096:biosynthesis*; D016209:Interleukin-8 / Q000096:biosynthesis*; D064726:Triple Negative Breast Neoplasms / Q000276:immunology* / Q000473:pathology*
chemical_list: D015850:Interleukin-6; D016209:Interleukin-8
keywords: EZH2; JAK/STAT; LPA; cytokine/chemokine; tandem inhibition; targeted therapy; transcriptional profiling; triple-negative breast cancer; tumor stem cell
references: Clin Cancer Res. 2009 Oct 15;15(20):6327-40
references: 19808870
references: Nature. 2012 Oct 4;490(7418):61-70
references: 23000897
references: Int J Cancer. 2010 Dec 15;127(12):2893-917
references: 21351269
references: Mol Cell. 2012 Aug 24;47(4):570-84
references: 22819326
references: J Clin Invest. 2011 Jul;121(7):2723-35
references: 21633165
references: Nature. 2012 Apr 18;486(7403):346-52
references: 22522925
references: Nature. 2012 Apr 04;486(7403):395-9
references: 22495314
references: Cancer Res. 2013 Jun 1;73(11):3470-80
references: 23633491